MediaTek unveiled the Dimensity 9600 Pro, its first smartphone processor built on TSMC's 2nm node, alongside the 3nm Dimensity 9600M. Both chips feature enhanced AI capabilities as the Taiwanese chipmaker intensifies competition with Qualcomm.
The new processors mark MediaTek's entry into TSMC's most advanced process technology. The 2nm Dimensity 9600 Pro represents a significant leap in manufacturing efficiency, while the 9600M operates on the 3nm node.
Both chips integrate upgraded AI performance to handle increasingly demanding on-device machine learning tasks. This aligns with industry trends toward localized AI processing in smartphones.
MediaTek's move targets premium smartphone segments where Qualcomm's Snapdragon processors have traditionally dominated. The company aims to secure design wins from major phone manufacturers seeking alternative flagship chipsets.
The unveiling underscores Taiwan's semiconductor manufacturing leadership, with TSMC continuing to supply cutting-edge nodes to regional chip designers. MediaTek's expansion into advanced nodes signals confidence in demand for high-performance mobile processors.
No pricing or availability details were announced. Phone manufacturers typically integrate new flagship chips into devices within 6-12 months of announcement.
HTC's Vive Eagle smart glasses offer privacy-focused features and intuitive controls, but struggle to justify their $499+ price tag in a market dominated by Meta's deeper pockets.
Agility Robotics introduced Digit 5, a humanoid robot designed to work safely alongside humans without physical barriers. The robot uses AI collision-avoidance software and new sensors to operate in shared workspaces.
General Motors is revamping its truck software to reduce driver distraction while introducing picture-in-picture displays for Apple CarPlay and Android Auto. The shift marks a departure from GM's previous resistance to phone mirroring in its vehicles.
Flow Neuroscience's FDA-approved headset is now available in the United States. The device costs $2,200 and aims to help patients reduce antidepressant dependence.